Pharmaceutical

CD70 CAR-T by UTC Therapeutics for B-Cell Non-Hodgkin Lymphoma: Likelihood of Approval

CD70 CAR-T is under clinical development by UTC Therapeutics and is currently in the Phase II in clinical pathway.

Aug 10, 2023 - 20:00
CD70 CAR-T is under clinical development by UTC Therapeutics and is currently in the Phase II in clinical pathway.
Read the original article

Tags:

Previous Article

CD70 CAR-T by UTC Therapeutics for Relapsed Chronic Lymphocytic Leukemia (CLL): ...

Next Article

CD70 CAR-T by UTC Therapeutics for Anaplastic Large Cell Lymphoma (ALCL): Likeli...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Can reforms restore faith in India’s pharma industry after cough syrup scandals?

Can reforms restore faith in India’s pharma industry af...

Sep 29, 2023

New research supports potential link between low-level lead exposure and liver injury

New research supports potential link between low-level ...

Nov 27, 2023

Opinion: CMS must protect access to the ‘gold standard of breast reconstruction’

Opinion: CMS must protect access to the ‘gold standard ...

Jun 30, 2023